Abiopharma

General Announcement: CHANGES IN SUBSTANTIAL SHAREHOLDERS INTEREST PURSUANT TO SECTION 138 OF THE COMPANIES ACT 2016

Smith+Nephew PLC Notification

PEPG Investors Have Opportunity to Lead PepGen Inc. Securities Fraud Lawsuit with the Schall Law Firm

FDA approve VORICONAZOLE

FDA approve SUGAMMADEX SODIUM

FDA approve GANAXOLONE

FDA approve BUMETANIDE

FDA approve DOXYCYCLINE HYCLATE

ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit with the Schall Law Firm

Smith+Nephew PLC Notification

Almirall and Absci Expand AI Drug Creation Collaboration Adding a Second Dermatology Target

HIGHCON SYSTM-M (HICN-M) was added to the list of traded instruments on TASE exchange

TASE symbol attribute type Security_Name was changed. Previous value: ZUR B13. New value: VALUE CAPITAL.

NASDAQ symbol attribute type Financial_Status was changed. Previous value: Deficient. New value: Normal.

Valneva Announces Removal of FDA-Recommended Pause on Use of Chikungunya Vaccine IXCHIQ® in Elderly and Updates to the Prescribing Information